Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Malignant mesenchymal tumor 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Radiotherapy 10Doxorubicin 10Ifosfamide 9Vincristine 8Filgrastim 8Cyclophosphamide 8Dactinomycin 7Etoposide 5Carboplatin 4sargramostim 3Irinotecan 3Trabectedin 2Topotecan 2Radiotherapy, Conformal 2Neoadjuvant Therapy 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Epirubicin 2Chemotherapy, Adjuvant 2trioctyl phosphine oxide 1romidepsin 1pegfilgrastim 1indolepropanol phosphate 1etoposide phosphate 1cixutumumab 1brostallicin 1Watchful Waiting 1Vinorelbine 1Temozolomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant mesenchymal tumor × NHS-IL12 immunocytokine × Clear all
NCT01417546 2021-10-18

NHS-IL12 for Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
72 enrolled

Malignant mesenchymal tumor, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡